The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
Fiche publication
Date publication
février 2017
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L,
Lien Pubmed
Résumé
Whether aminosalicylates or thiopurines reduce the risk of colorectal cancer (CRC) in inflammatory bowel (IBD) disease is controversial.
Mots clés
Adult, Aged, Aminosalicylic Acids, therapeutic use, Anti-Inflammatory Agents, Non-Steroidal, therapeutic use, Case-Control Studies, Colitis, diagnosis, Colorectal Neoplasms, diagnosis, Female, Humans, Inflammatory Bowel Diseases, diagnosis, Male, Mesalamine, therapeutic use, Middle Aged, Multivariate Analysis, Prospective Studies, Retrospective Studies, Risk Factors, Treatment Outcome
Référence
Aliment. Pharmacol. Ther.. 2017 Feb;45(4):533-541